Disease · MONDO_0044348
Comparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 14 of 14
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Regimen A (PBSCT and BMT) vs Regimen B (UBCT): Number of Participants With Infections | 57 of 84 | 9 of 14 | 98 | NCT00919503 | Trial comparisons |
| Regimen A (PBSCT and BMT) vs Regimen B (UBCT): deaths from any cause | 7 of 84 | 6 of 14 | 98 | NCT00919503 | Trial comparisons |
| Regimen A (PBSCT and BMT) vs Regimen B (UBCT): Overall Survival | 80 of 84 | 9 of 14 | 98 | NCT00919503 | Trial comparisons |
| Regimen A (PBSCT and BMT) vs Regimen B (UBCT): Non-relapse Mortality | 2 of 84 | 5 of 14 | 98 | NCT00919503 | Trial comparisons |
| Regimen A (PBSCT and BMT) vs Regimen B (UBCT): serious adverse events | 17 of 84 | 5 of 14 | 98 | NCT00919503 | Trial comparisons |
| Regimen A (PBSCT and BMT) vs Regimen B (UBCT): Number of Patients With Grade II-IV Acute Graft-versus-host Disease | 44 of 84 | 8 of 12 | 96 | NCT00919503 | Trial comparisons |
| Regimen A (PBSCT and BMT) vs Regimen B (UBCT): Disease Response at One Year Following Hematopoietic Cell Transplantation | 78 of 84 | 8 of 11 | 95 | NCT00919503 | Trial comparisons |
| Regimen A (PBSCT and BMT) vs Regimen B (UBCT): Preliminary Efficacy | 83 of 84 | 10 of 11 | 95 | NCT00919503 | Trial comparisons |
| Regimen A (PBSCT and BMT) vs Regimen B (UBCT): Number of Patients With of Chronic Graft-versus-host Disease | 29 of 84 | 5 of 11 | 95 | NCT00919503 | Trial comparisons |
| Regimen A (PBSCT and BMT) vs Regimen B (UBCT): Immune Reconstitution Following Hematopoietic Cell Transplantation | 39 of 73 | 4 of 9 | 82 | NCT00919503 | Trial comparisons |
| HLA-identical Sibling Transplant vs Unrelated Matched or Single Antigen Mismatched Transplant: Number of Patients With Successful Donor Engraftment | 2 of 3 | 1 of 1 | 4 | NCT00579111 | Trial comparisons |
| HLA-identical Sibling Transplant vs Unrelated Matched or Single Antigen Mismatched Transplant: Number of Patients With Treatment Related Grade III or IV Non-hematological Toxicity | 1 of 3 | 0 of 1 | 4 | NCT00579111 | Trial comparisons |
| HLA-identical Sibling Transplant vs Unrelated Matched or Single Antigen Mismatched Transplant: serious adverse events | 2 of 3 | 0 of 1 | 4 | NCT00579111 | Trial comparisons |
| Recipients vs Donors: serious adverse events | 0 of 2 | 0 of 1 | 3 | NCT01534676 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0044348/comparisons